|
|
||||||||||||||
|
|
|||||||||||||||
Reviews |
1 Head of Neuro-ophthalmology, Neuro-ophthalmology Unit, Department of Ophthalmology, Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
2 Sieratzki Chair of Neurology, Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Correspondence to:
Correspondence to:
Dr Anat Kesler, Neuro-ophthalmology Unit, Department of Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel;
kesler@netvision.net.il
| The first 150 words of the full text of this article appear below. |
Movement disorders consist of a diverse and heterogeneous group of neurological impairments, frequently accompanied by abnormalities in ocular motility and visual perception. Parkinsons disease is one of the more common and is caused by degeneration of dopaminergic neurons in the substantia nigra of the midbrain with loss of dopamine terminals in the basal ganglia. It is regarded primarily as a disorder of the motor system with bradykinesia, rigidity, and tremor as its main features. However, autonomic, cognitive, and sensory symptoms frequently occur as well.
Visual disturbance is not considered to be one of the cardinal clinical symptoms of Parkinsons disease even though blurred vision, photophobia, asthenopia (weakness or fatigue of the eyes, usually accompanied by headache and dimming of vision), or trouble reading are common, often significantly interfering with the patients quality of life.1,2 Visual problems have particular significance because of the Parkinson patients impaired mobility and the implications for
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |